Metropolis Healthcare Ltd. · NSE:METROPOLIS
Metropolis Healthcare — Q3 FY2026 Earnings Presentation
30 slides from Metropolis Healthcare's earnings presentation, Feb 4, 2026
Slide 1: Regulation 30 cover letter to stock exchanges
Ref: MHL/Sec&Legal/2025-26/88 February 04, 2026 To, BSE Limited National Stock Exchange of India Ltd. Scrip Code: 542650 Scrip Symbol: METROPOLIS Dear Sir/Madam, Sub: Investor Presentation Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we a
Slide 2: Q3 & 9MFY26 Investor Presentation
METROPOLIS HEALTHCARE LIMITED Q3 & 9MFY26 INVESTOR PRESENTATION
Slide 3: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Metropolis Healthcare Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any
Slide 4: Metropolis – Diagnostics that's trusted by doctors and patients alike
Metropolis – Diagnostics that’s trusted by doctors and patients alike OUR VISION To be a respected healthcare brand trusted by 43+ years of clinicians, patients and stakeholders. 11% CAGR credible Positively impact the lives of patients in their revenue growth experience most anxious times and turn
Slide 5: Performance & Company Updates – Q3FY26
Performance & Company Updates – Q3FY26 Important Updates & Definitions: 1. MHL Group – Includes acquisitions of Core Diagnostics, DAPIC – Dehradun, Scientific Pathology – Agra and Ambika - Kolhapur 2. MHL Organic – Excludes recent acquisitions of Core Diagnostics, DAPIC – Dehradun, Scientific MHL Gr
Slide 6: Q3 & 9MFY26 Key Financials – MHL Organic
Q3 & 9MFY26 Key Financials – MHL Organic Q3FY26 • Strong organic business momentum in Q3 Revenue EBITDA PAT* FY26, with revenue up 15% YoY, driven by higher patient throughput, test volumes, and improved realizations INR 371 Cr INR 93 Cr INR 48 Cr +15% YoY +29% YoY +52% YoY • EBITDA margin expanded
Slide 7: Q3 & 9MFY26 Key Financials – MHL Group
Q3 & 9MFY26 Key Financials – MHL Group Q3FY26 • Revenue growth fueled by sustained Revenue EBITDA PAT* momentum in preventive and wellness health check-ups under TruHealth, along with a strong increase in specialty testing INR 406 Cr INR 95 Cr INR 51 Cr volumes across both B2C and B2B channels +26%
Slide 8: Q3FY26 Key Performance Indicators – MHL Organic
Q3FY26 Key Performance Indicators MHL Organic Excludes recent acquisitions of Core Diagnostics, DAPIC – Dehradun, Scientific Pathology – Agra & Ambika - Kolhapur 6
Slide 9: Q3FY26 Key Performance Indicators
Q3FY26 Key Performance Indicators Patient Volume B2C Revenue B2B Revenue • Strong volume-led growth, with high single- digit increases in patient and test volumes, reflecting sustained demand across markets 3.3 Mn INR 223 Cr INR 148 Cr • Balanced B2C and B2B momentum, driven by +9% YoY +15% YoY +15%
Slide 10: Consistently Delivering Patient & Test Volume Growth
Consistently Delivering Patient & Test Volume Growth Patient Volume (in Mn) Test Volume (in Mn) Q3FY26 Segment Q3FY26 Segment Revenue Contribution Growth 9.7% 9% 6% 8% 16% Routine 12% Routine 19% 3.06 3.32 6.44 6.99 Semi-Special Semi-Special 9% Specialty 27% Specialty 16% TruHealth 38% TruHealth 25%
Slide 11: B2C revenue growth @ 15% YoY
B2C revenue growth @ 15% YoY • B2C patient volumes increased by 7%, while revenue per patient grew 8%, supported by scientific-led upselling. • Premium TruHealth packs and consult 60% bundles significantly lifted B2C revenue quality and RPP +21% • Specialty growth accelerated through clinician conne
Slide 12: B2B revenue growing by 15% YoY
B2B revenue growing by 15% YoY • Strategic B2B push mitigated seasonality, sustaining growth 40% momentum with volume growth of 11% +50% and 4% rise in RPP • Specialty and corporate client additions +16% lifted mix and scale • Digital partner integration, enhanced reliability, query resolution platf
Slide 13: TruHealth Revenue grew @ 25% YoY for Q3FY26
TruHealth Revenue grew @ 25% YoY for Q3FY26 o Strong Revenue Momentum, Premium Mix & Digital Acceleration Growth • TruHealth contribution increased to 19% (vs 17% Q3FY25) driven by mix upgrade due to adoption of MetAdvisor (AI- powered Recommendation Engine) across touchpoints • Premium TruHealth po
Slide 14: Speciality Revenue grew @ 16% YoY for Q3FY26
Speciality Revenue grew @ 16% YoY for Q3FY26 o Leveraging Core diagnostic capabilities in specialized & super-specialized testing to drive Specialty cross-selling across Metropolis’ nationwide B2C and B2B network. Growth o Distinct capabilities and end-to-end services under one roof enabling increas
Slide 15: Q3FY26 Key Performance Indicators – MHL Group
Q3FY26 Key Performance Indicators MHL Group Includes recent acquisitions of Core Diagnostics, DAPIC - Dehradun, Scientific Pathology – Agra and Ambika - Kolhapur 13
Slide 16: Q3FY26 Key Performance Indicators
Q3FY26 Key Performance Indicators Q3FY26 Segment Contribution Patient Volume B2C Revenue B2B Revenue 17% 17% Routine Semi-Special 3.5 Mn INR 232 Cr INR 174 Cr Specialty 26% +14% YoY +19% YoY +35% YoY TruHealth 40% Q3FY26 Segment Revenue Growth Test Volume RPT RPP Routine 16% Semi-Special 15% 7.3 Mn
Slide 17: Diversified Revenue contribution across geographies
Diversified Revenue contribution across geographies Contribution from North India has increased to 17% Revenue Contribution Revenue Contribution (MHL Categorisation) By Region West 31% 28% South Q3FY25 51% Q3FY26 57% 4% North 5% East 8% 17% Revenue Contribution Revenue Contribution (MHL Categorisati
Slide 18: Building a scalable efficient network
Building a scalable efficient network Laboratory Network Service Network 210 219 199 4,150 4,536 4862 175 3,675 964 161 870 805 +2,307 119 124 125 +94 2,731 2,555 3,134 754 2,336 704 Centres Labs 575 598 498 3,135 3,261 2,914 2,594 2,105 Rural 1,873 1,806 1,506 Franchisee 325 327 431 531 637 Owned 2
Slide 19: Q3FY26 Profit & Loss Statement
Q3FY26 Profit & Loss Statement Q3FY26 Q3FY26 Profit & Loss Statement (Rs. Crs.) Q3FY25 Y-o-Y Y-o-Y (MHL Organic) (MHL Group) Revenue from Operations 323 371 15.0% 406 25.8% Total Cost 251 279 311 EBITDA 72 93 29.3% 95 32.4% EBITDA Margin (%) 22.2% 25.0% 280 bps 23.4% 120 bps Depreciation 28 29 32 Ot
Slide 20: 9MFY26 Profit & Loss Statement
9MFY26 Profit & Loss Statement 9MFY26 9MFY26 Profit & Loss Statement (Rs. Crs.) 9MFY25 Y-o-Y (MHL Y-o-Y (MHL Organic) Group) Revenue from Operations 986 1118 13.4% 1,221 23.9% Total Cost 745 833 928 EBITDA 241 285 18.1% 293 21.4% EBITDA Margin (%) 24.5% 25.5% 100 bps 24.0% -50 bps Depreciation 80 88
Slide 21: Metropolis 3.0
Metropolis 3.0 METROP®OLIS
Slide 22: Key Pillars of Metropolis 3.0 Strategy – poised to grow further
Key Pillars of Metropolis 3.0 Strategy – poised to grow further 1 Strengthening the Core Expand market share in core and new geographies with focus on specialized and wellness testing, strengthening Top 800 towns via Micro Market Strategy, T3 Acceleration, and breakthrough asset Expand to Adjacencie
Slide 23: Driving business growth through Digital Transformation
Driving business growth through Digital Transformation Metropolis is a unique Healthcare Company equipped with CDP, Marketing Cloud, Service Cloud, Sales Cloud, Partner Portal Accurate Efficient 360-Degree Opportunity Case Relationship Reporting & Cross Channel Enhanced Efficient Patient Billing & P
Slide 24: Scientifically driven with strong focus on quality, research and academics
Scientifically driven with strong focus on quality, research and academics Scientific Expansion in Test Menu • New test launched across Oncology, Nephrology, Gynecology and 57+ New Tests added in H1FY26 Infectious and Chronic disease segment • Focus on NGS/molecular genomics segment growing driven b
Slide 25: Metropolis ESG Goals
Metropolis ESG Goals • Carbon Neutrality by 2043 Emission Goals for a Greener Tomorrow • 45% reduction in emissions intensity by 2030 Well identified ESG Focus Areas and assessments created e as per the materiality matrix based on the GRI, SASB and SDG Frameworks. • Zero waste in offices by 2030 Ach
Slide 26: Key ESG Plans
Key ESG Plans Emissions & Water & Waste Employee Risk Management Patient Privacy and Energy Management Recruitment, Electronic Health Development and Records • Achieve 5% reduction in Retention • Achieve 10% reduction in water usage through energy consumption through • Career 2.0 Campaign to increas
Slide 27: CSR at Metropolis – creating a positive impact
CSR at Metropolis – creating a positive impact Preventive Healthcare MedEngage Too Shy to Ask Projects (TSTA) • 365 scholarships, including 43 research grants, • TSTA Rural focused on adolescent reproductive • 1,000 TB patients received nutritional support in were awarded under the MedEngage Program
Slide 28: 'Promoter led – Professionally driven' organisation
‘Promoter led – Professionally driven’ organisation Dr. Sushil Shah Ameera Shah Surendran Chemmenkotil Founder & Non – Executive Promoter & Executive Chairperson Managing Director Non - Independent Director Dynamic Leadership Team for Next Level of Growth Dr. Nilesh Shah Sameer Patel Diya Suri Dr. K
Slide 29: Recent Awards and Accolades
Recent Awards and Accolades Dec’25 Ameera Shah – Most Powerful Women in Business by Business Today for the year 2025 Dr Sushil Shah and Ameera Shah felicitated with the Hurun India’s Family Business Sept’25 Excellence Award for the year 2025. Sept’25 Ameera Shah - Influential Leader of India Award 2
Slide 30: For further information, please contact
For further information, please contact: Company : Investor Relations Advisors : http://www.sgapl.net/images/sgapl_logo.jpg Metropolis Healthcare Ltd. Strategic Growth Advisors Pvt. Ltd. CIN – L73100MH2000PLC192798 CIN - U74140MH2010PTC204285 Mr. Kamlesh Kulkarni Mr. Shogun Jain / Mr. Sagar Shroff E
Metropolis Healthcare — Q3 FY2026 Earnings Presentation on 6ix